Shares of Elite Pharmaceuticals, Inc. (ELTP) have lost 15.9% since the company reported its earnings for the quarter ended Sept. 30, 2025. This compares with the S&P 500 Index’s 2.2% loss over the same period. Over the past month, Elite stock plunged 4.9%, while the S&P 500 slipped 2%.ELTP’s Earnings and Revenue PerformanceIn the second quarter of fiscal 2026, Elite Pharmaceuticals posted revenues of $36.3 million, up 92.4% year over year from $18.9 million, driven largely by the launch and rapid expansion ...